全文获取类型
收费全文 | 149篇 |
免费 | 16篇 |
国内免费 | 14篇 |
专业分类
儿科学 | 3篇 |
妇产科学 | 1篇 |
口腔科学 | 1篇 |
临床医学 | 5篇 |
内科学 | 42篇 |
特种医学 | 71篇 |
外科学 | 11篇 |
综合类 | 5篇 |
预防医学 | 1篇 |
药学 | 6篇 |
肿瘤学 | 33篇 |
出版年
2023年 | 20篇 |
2022年 | 12篇 |
2021年 | 27篇 |
2020年 | 10篇 |
2019年 | 14篇 |
2018年 | 16篇 |
2017年 | 10篇 |
2016年 | 10篇 |
2015年 | 15篇 |
2014年 | 11篇 |
2013年 | 9篇 |
2012年 | 4篇 |
2011年 | 4篇 |
2010年 | 1篇 |
2009年 | 2篇 |
2008年 | 5篇 |
2007年 | 2篇 |
2006年 | 2篇 |
2005年 | 1篇 |
2004年 | 2篇 |
1999年 | 2篇 |
排序方式: 共有179条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
6.
7.
《Journal of vascular and interventional radiology : JVIR》2021,32(8):1103-1112.e12
PurposeTo investigate the feasibility, safety, and absorbed-dose distribution of prostatic artery radioembolization (RE) in a canine model.Materials and MethodsFourteen male castrated beagles received dihydroandrosterone/estradiol to induce prostatic hyperplasia for the duration of the study. Each dog underwent fluoroscopic prostatic artery catheterization. Yttrium-90 (90Y) microspheres (TheraSphere; Boston Scientific, Marlborough, Massachusetts) were delivered to 1 prostatic hemigland (dose escalation from 60 to 200 Gy), with the contralateral side serving as a control. Assessments for adverse events were performed throughout the follow-up (Common Terminology Criteria for Adverse Events v5.0). Positron emission tomography/magnetic resonance (MR) imaging provided a confirmation after the delivery of absorbed-dose distribution. MR imaging was performed before and 3, 20, and 40 days after RE. Tissue harvest of the prostate, rectum, bladder, urethra, penis, and neurovascular bundles was performed 60 days after RE.ResultsAll the animals successfully underwent RE. Positron emission tomography/MR imaging demonstrated localization to and good coverage of only the treated hemigland. No adverse events occurred. The MR imaging showed a significant dose-dependent decrease in the treated hemigland size at 40 days (25%–60%, P < .001). No extraprostatic radiographic changes were observed. Necropsy demonstrated no gross rectal, urethral, penile, or bladder changes. Histology revealed RE-induced changes in the treated prostatic tissues of the highest dose group, with gland atrophy and focal necrosis. No extraprostatic RE-related histologic findings were observed.ConclusionsProstate 90Y RE is safe and feasible in a canine model and leads to focal dose-dependent changes in the gland without inducing unwanted extraprostatic effects. These results suggest that an investigation of nonoperative prostate cancer is warranted. 相似文献
8.
9.
Judith White Grace Carolan-Rees Megan Dale Hannah E. Patrick Teik Choon See Jon K. Bell Derek M. Manas Adrian Crellin Nicholas J. Slevin Ricky A. Sharma 《Journal of vascular and interventional radiology : JVIR》2019,30(8):1185-1192
PurposeTo evaluate the safety and efficacy of yttrium-90 transarterial radioembolization (TARE) for the treatment of unresectable, chemotherapy-refractory intrahepatic cholangiocarcinoma (ICC).MethodsA prospective, observational study was carried out in 10 centers between 2013 and 2017. TARE plus standard care was delivered to patients with unresectable, chemotherapy-refractory or chemotherapy-intolerant ICC. Primary outcome was overall survival. Secondary outcomes included safety, progression-free survival (PFS), and liver-specific progression-free survival (LPFS).ResultsSixty-one patients were treated with TARE. Patients were 53% male; median age was 64 years; 91% had performance status 0/1; 92% had received prior chemotherapy; and 59% had no extrahepatic disease. Median follow-up was 13.9 months (95% confidence interval [CI], 9.6–18.1). Overall survival was 8.7 months (95% CI, 5.3–12.1), and 37% of patients survived to 12 months. PFS was 2.8 months (95% CI, 2.6–3.1), and LPFS was 3.1 months (95% CI, 1.3–4.8). One severe complication (abdominal pain) occurred at the time of the TARE procedure. Thirty patients experienced a total of 49 adverse events, of which 8% were grade ≥3; most common were grade 1–2 fatigue and abdominal pain. A total of 77 abnormal laboratory value events were recorded, of which 4% were grade ≥3.ConclusionsPatients with advanced ICC have limited therapeutic options and a poor prognosis. This prospective study examined the survival of patients with unresectable, chemotherapy-refractory primary ICC treated with TARE in real-world practice. The results demonstrate that this treatment merits further investigation in this patient cohort in a larger study, including collection of patient-reported outcomes. 相似文献
10.
Preparation and evaluation of 188Re sulfide colloidal nanoparticles loaded biodegradable poly (L‐lactic acid) microspheres for radioembolization therapy 下载免费PDF全文
Mina Jamre Mojtaba Shamsaei Mostafa Erfani Sodeh Sadjadi Mohammad Ghannadi Maragheh 《Journal of labelled compounds & radiopharmaceuticals》2018,61(8):586-594
Radioembolization with radioactive microspheres has been an effective method for the treatment of liver lesions. The aim of this study was to prepare carrier‐free 188Re loaded poly (L‐lactic acid) (PLLA) microspheres through 188Re sulfide colloidal nanoparticles (188Re‐SC nanoparticles). The formation of 188Re‐SC nanoparticles was confirmed by ultraviolet‐visible spectrophotometry. The labeling yield of 188Re‐SC nanoparticles was verified using the RTLC method. Effects of synthesis parameters on morphology and size of prepared 188Re‐sulfide colloidal‐PLLA microspheres (188Re‐SC‐PLLA microspheres) were studied by scanning electron microscopy. In vitro stability of 188Re‐SC‐PLLA microspheres was investigated in normal saline at room temperature and in human serum at 37°C. In vivo distribution studies and gamma camera imaging were performed in healthy BALB / c mice. The microspheres could be prepared with sizes between 13 and 48 μm (modal value 29 μm) and radiolabeling efficiency >99%. After incubation, the microspheres were found stable in vitro up to 72 hours. The biodistribution after intravenous injection in healthy BALB / c mice showed high accumulation in lung as a first capture pathway organ for microsphere followed by great retention over 48 hours for these microspheres. These data show that 188Re‐SC‐PLLA microspheres are suitable candidate for clinical studies. 相似文献